{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:49:40Z","timestamp":1784695780123,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.thromres.2013.06.015","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T20:30:36Z","timestamp":1372797036000},"page":"e105-e111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays"],"prefix":"10.1016","volume":"132","author":[{"given":"Argirios E.","family":"Tsantes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanos","family":"Bonovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argiri","family":"Gialeraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kottaridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Kyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Styliani","family":"Kokori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Douramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Kopterides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Karakitsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lekakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violetta","family":"Kapsimali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2013.06.015_bb0005","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.06.015_bb0010","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nm1102-1227","article-title":"Platelets in atherothrombosis","volume":"8","author":"Ruggeri","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.thromres.2013.06.015_bb0015","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Clopidogrel for the Reduction of Events During Observation. Early and sustained oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2013.06.015_bb0020","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo controlled trial","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.06.015_bb0025","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.amjcard.2005.01.049","article-title":"Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials","volume":"95","author":"Serebruany","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.thromres.2013.06.015_bb0030","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2013.06.015_bb0035","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/j.jacc.2005.07.056","article-title":"Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study","volume":"46","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.06.015_bb0040","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2013.06.015_bb0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcin.2008.01.005","article-title":"Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention","volume":"1","author":"Kereiakes","year":"2008","journal-title":"J Am Coll Cardiol Intv"},{"key":"10.1016\/j.thromres.2013.06.015_bb0050","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.06.015_bb0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2013.06.015_bb0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2013.06.015_bb0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","article-title":"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study","volume":"373","author":"Collet","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.06.015_bb0070","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 Genotype, clopidogrel Metabolism, Platelet Function, and Cardiovascular Events A Systematic Review and Meta-analysis","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2013.06.015_bb0075","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jacc.2008.07.055","article-title":"Calcium-channel blockers reduce the antiplatelet effect of clopidogrel","volume":"52","author":"Siller-Matula","year":"2008","journal-title":"Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.06.015_bb0080","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1592\/phco.28.12.1483","article-title":"Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects","volume":"28","author":"Farid","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.thromres.2013.06.015_bb0085","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/j.1538-7836.2006.02162.x","article-title":"Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin","volume":"4","author":"Gilard","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2013.06.015_bb0090","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.06.015_bb0095","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0091270008315310","article-title":"Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel","volume":"48","author":"Small","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2013.06.015_bb0100","doi-asserted-by":"crossref","first-page":"148.e1","DOI":"10.1016\/j.ahj.2008.09.017","article-title":"Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel","volume":"157","author":"Siller-Matula","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.thromres.2013.06.015_bb0105","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and plasugrel with or without a proton pump inhibitor: an analysis of two randomized trials","volume":"374","author":"O\u2019Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.06.015_bb0110","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis","volume":"56","author":"Hulot","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.06.015_bb0115","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.thromres.2011.05.008","article-title":"The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent","volume":"128","author":"Gremmel","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2013.06.015_bb0120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/09537104.2012.689037","article-title":"Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance","volume":"23","author":"Tsantes","year":"2012","journal-title":"Platelets"},{"key":"10.1016\/j.thromres.2013.06.015_bb0125","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.thromres.2011.11.019","article-title":"Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests","volume":"129","author":"Gremmel","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2013.06.015_bb0130","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.06.015_bb0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/ajg.2009.638","article-title":"Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?","volume":"105","author":"Laine","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.thromres.2013.06.015_bb0140","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2009.05.050","article-title":"Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study","volume":"54","author":"Cuisset","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.06.015_bb0145","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2013.06.015_bb0150","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"Breet","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2013.06.015_bb0155","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2012.11.040","volume":"61","author":"Frelinger","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.thromres.2013.06.015_bb0160","first-page":"313","article-title":"Aspirin and clopidogrel response variability: review of the published literature","volume":"35","author":"Ferguson","year":"2008","journal-title":"Tex Heart Inst J"},{"key":"10.1016\/j.thromres.2013.06.015_bb0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jcph.17","article-title":"Clopidogrel, CYP2C19, and a Black Box","volume":"53","author":"Ford","year":"2013","journal-title":"J Clin Pharmacol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813002661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384813002661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T23:48:32Z","timestamp":1563320912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384813002661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0049384813002661"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2013.06.015","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2013.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}